Pharmafile Logo
Pharmafocus logo
Advanced Search

Erbitux

Showing 9 posts of 24 posts found.

Roche’s Avastin (bevacizumab)

NHS failed to use extra cancer drug funds

June 17, 2011
Sales and Marketing Cancer, Cancer Drugs Fund, Erbitux, avastin

The million pound fund set up to increase NHS uptake of new cancer drugs was widely underused, with just over …

News
Merck Serono headquarters

Erbitux meets gold standard in rectal cancer

June 7, 2011
Research and Development, Sales and Marketing Erbitux, Merck Serono, rectal cancer

Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …

News
Erbitux (cetixumab)

Merck re-submits Erbitux to the EMA for lung cancer

March 30, 2011
Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer

Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …

News

Erbitux ‘now standard of care’ in KRAS patients

June 3, 2010
Sales and Marketing Erbitux, Merck Serono

A new survey suggests Merck Serono’s Erbitux has become a standard of care for KRAS wild-type metastatic colorectal cancer The …

News

Merck KGaA posts modest revenue increase

February 24, 2010
2009 financials, Erbitux, Merck KGaA, Merck Serono, Rebif

German pharma company Merck has posted a modest rise in revenue amidst strong pharma growth.  Revenues increased 2.1% to 7.7 …

News

Merck Serono asks EMEA to re-think Erbitux rejection

July 30, 2009
Research and Development, Sales and Marketing Cancer, EMEA, Erbitux, Europe, Merck Serono

Merck Serono is to appeal against the European rejection of Erbitux as a lung cancer treatment.Erbitux has been rejected as …

News

NICE rejects Erbitux in head and neck cancer

June 24, 2009
Research and Development, Sales and Marketing Erbitux, Merck Serono, NICE

News

NICE approves Erbitux for colon cancer

June 1, 2009
Research and Development, Sales and Marketing Erbitux, NICE

NICE has approved Merck Serono's Erbitux, making it a first-line therapy for many patients with a certain type of metastatic …

News

Merck Serono seeks first-line use for Erbitux

September 6, 2007
Sales and Marketing Erbitux

Merck Serono has seeking a broader licence for its cancer drug Erbitux in Europe to include use as a first-line …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025